# SELLAS (SLS): Phase 3 Data, a 156% Day and a $150M Offering

> Source: IndicatorStack, https://indicatorstack.com/catalysts/sls-2026-11-17-data-and-offering. Updated Nov 19, 2026, 4:41 AM ET. Prices are indicative. General market information, not a recommendation to buy or sell any security.

SELLAS Life Sciences (SLS) released positive pivotal Phase 3 REGAL trial data at 7:00 AM ET on Tuesday, November 17, and the stock went from Monday’s $7.47 close to as high as $34.00 before the open. It finished the session +156.4% at $19.15 on 15.7 times its 20-day average volume. After the close it proposed a $150 million offering, and on Wednesday night priced it at $13.00 a share. Here is how it traded, turn by turn, and how LiveChart’s stack read each one.

Catalyst Reaction by IndicatorStack, published Nov 19, 2026, 12:00 AM ET. NASDAQ: SLS, Biotechnology. All times ET.

## The numbers

- +156.4% Tuesday’s close ($7.47 to $19.15, high $34.00)
- 15.7× its 20-day average volume (120M shares on the day)
- $13.00 offering price (27.6% under Wednesday’s $17.95 close)
- +5.7% shares outstanding from the offering (11.5M new shares on 204M, 6.5% with the option)

## How the stack read it, checkpoint by checkpoint

| Checkpoint | When | Price | 5m stack bias | Compass |
| --- | --- | --- | --- | --- |
| Before | Mon close | $7.47 | Bearish, weakening | Tailwind down |
| Into the open | Tue 9:30 AM | $24.04 | Bullish, weakening | Tailwind up |
| 30 minutes in | Tue 10:00 AM | $17.79 | Bullish, weakening | Tailwind up |
| At the close | Tue 4:00 PM | $19.18 | Bearish, firm | Higher timeframes still up |
| Wednesday’s close | Wed 4:00 PM | $17.94 | Bearish, firm | Higher timeframes still up |

## Timeline

### Tuesday, November 17

- 6:50 AM: Trigger marked a long at $8.00 (Hypothetical, default settings: reached $31.02 at 8:30 AM for +237.8R (target))
- 7:00 AM: Positive pivotal Phase 3 REGAL trial data (Press release, GlobeNewsWire)
- 7:14 AM: Current report (Form 8-K) filed (Accepted by the SEC at 7:14:19 AM ET)
- 8:30 AM: Premarket high $34.00 (+355.2% from the prior close)
- 8:40 AM: 5-minute stack bias turned bullish (at $25.25)
- 9:30 AM: Opened at $24.11 (+222.8% from Monday’s $7.47 close)
- 9:55 AM: Session low $16.70
- 11:20 AM: Tripwire flagged a trap at the highs (a push through resistance that failed to hold, at $21.33)
- 12:30 PM: 5-minute stack bias went neutral (at $20.16, its inputs no longer agreeing)
- 12:45 PM: Trigger marked a long at $20.25 (Hypothetical, default settings: closed at $18.77 at 1:15 PM for −1.2R (stop))
- 1:10 PM: 5-minute stack bias turned bearish (at $19.40)
- 1:20 PM: Tripwire flagged a trap at the lows (a push through support that failed to hold, at $18.97)
- 3:50 PM: Trigger marked a short at $18.99 (Hypothetical, default settings: reached $16.98 at 4:05 PM for +3.2R (target))
- 4:00 PM: Closed at $19.15, +156.4% on the day (120M shares, 15.7× its 20-day average)
- 4:01 PM: Proposed $150.0 million underwritten public offering (Press release, GlobeNewsWire)
- 4:14 PM: Prospectus supplement (Form 424B5) filed (Accepted by the SEC at 4:14:29 PM ET)

### Wednesday, November 18

- 8:40 AM: 5-minute stack bias turned bullish (at $19.05)
- 9:30 AM: Opened at $19.51 (+1.9% from Tuesday’s $19.15 close)
- 9:40 AM: Session low $17.22
- 9:40 AM: 5-minute stack bias went neutral (at $17.64, its inputs no longer agreeing)
- 10:05 AM: 5-minute stack bias turned bullish (at $19.80)
- 11:30 AM: Session high $21.40
- 1:30 PM: 5-minute stack bias went neutral (at $19.37, its inputs no longer agreeing)
- 2:00 PM: 5-minute stack bias turned bearish (at $18.70)
- 4:00 PM: Closed at $17.95, −6.3% on the day (35.8M shares, 2.7× its 20-day average)
- 9:59 PM: Pricing of $150.0 million underwritten public offering (Press release, GlobeNewsWire)

### Scheduled

- November 20: The offering is expected to close (per the company’s pricing release)

## Before the catalyst (Monday, November 16)

SELLAS Life Sciences closed Monday at $7.47. The 5-minute stack bias was bearish (weakening), since 11:30 AM: under VWAP 7.67 and momentum down. Compass read “Tailwind down” (15m ↘ 1h ↘ 2h ↘ 4h ↘ D ↓). Undertow: volume surge, sellers hitting the bid. Tripwire: Shorts: Clean, nothing major in the way. Its Next row read “Bounce, resistance to hold at 7.67 (VWAP)”.

Over the year before, it had traded between $1.39 and $15.88. The week before, on Thursday, November 12, the company had announced third quarter 2026 financial results at 4:05 PM ET.

## The Phase 3 data and a 156% session (Tuesday, November 17)

The release crossed at 7:00 AM ET, with the company’s Form 8-K accepted by the SEC at 7:14 AM. Premarket trading carried it to $34.00 by 8:30 AM, +355% from the prior close, on 702K shares before the bell. It opened at $24.11, +222.8%, and the regular session ranged from $16.70 to $24.89 before closing at $19.15. It did this on a day SPY fell 1.0% and XBI, the biotechnology ETF, fell 0.4%.

Into the open the stack read it as bullish (weakening) with 5 of 5 higher timeframes up, and Undertow read “sellers pushing back”. Thirty minutes in, the picture had changed: price was below VWAP at $20.79 and the Next row read “Lost VWAP 20.79, buyers need a reclaim”. By the close the 5-minute bias was bearish from 1:10 PM, while Compass still read “Higher timeframes still up”: the day’s trend on the 5-minute chart had turned while the higher timeframes it is measured against had not.

## Between the offering’s proposal and its pricing (Wednesday, November 18)

It opened at $19.51 (+1.9%) and traded from $17.22 to $21.40, closing at $17.95, −6.3% on 35.8M shares, still 2.7 times its 20-day average. The 5-minute stack bias was bearish (firm), since 2:00 PM: under VWAP 19.22 and a falling SMA, momentum down and trend strength with the sellers. Compass read “Higher timeframes still up” (15m ↘ 1h ↗ 2h ↗ 4h ↗ D ↗). Undertow: volume surge, sellers hitting the bid. Tripwire: Shorts: Clean, nothing major in the way.

After hours it last traded at $17.98, with Undertow reading “selling drying up”. Then, at 9:59 PM ET, the company published pricing of $150.0 million underwritten public offering: 11,538,462 shares at $13.00, 27.6% under the $17.95 close.

## Supply

|  |  |  |
| --- | --- | --- |
| Shares outstanding | 204M | as reported to the SEC |
| Float | 202M | 99% of shares outstanding |
| Offering | 11.5M shares at $13.00 | $150M gross, plus an option on 1.7M more |
| After the offering | 215M shares | +5.7% (+6.5% with the option) |
| Value at the offering price | $2.8B | all shares after the offering, at $13.00 |
| Reverse splits on record | 3 | 1-for-50 reverse split, November 8, 2019; 1-for-30 reverse split, January 2, 2018; 1-for-20 reverse split, November 14, 2016 |
| Last insider purchase | November 19, 2025 | 63K shares at $1.59 by Kalin Katherine Bach (director) |
| Last insider sale | December 5, 2022 | 6K shares at $2.61 |

## Sources

- Wed Nov 18, 9:59 PM ET, Press release: Pricing of $150.0 million underwritten public offering (GlobeNewsWire) https://www.globenewswire.com/news-release/2026/11/19/3406277/0/en/sellas-life-sciences-announces-pricing-of-150-0-million-underwritten-public-offering.html
- Tue Nov 17, 4:14 PM ET, SEC filing: Prospectus supplement (Form 424B5) (SEC EDGAR) https://www.sec.gov/Archives/edgar/data/1390478/000110465926129063/tm2629996d1_424b5.htm
- Tue Nov 17, 4:01 PM ET, Press release: Proposed $150.0 million underwritten public offering (GlobeNewsWire) https://www.globenewswire.com/news-release/2026/11/17/3405168/0/en/sellas-life-sciences-announces-proposed-150-0-million-underwritten-public-offering.html
- Tue Nov 17, 7:14 AM ET, SEC filing: Current report (Form 8-K) (SEC EDGAR) https://www.sec.gov/Archives/edgar/data/1390478/000110465926128825/tm2629947d1_8k.htm
- Tue Nov 17, 7:00 AM ET, Press release: Positive pivotal Phase 3 REGAL trial data (GlobeNewsWire) https://www.globenewswire.com/news-release/2026/11/17/3404429/0/en/sellas-life-sciences-announces-positive-pivotal-phase-3-regal-trial-data-showing-immunotherapeutic-cancer-vaccine-galinpepimut-s-gps-demonstrated-a-statistically-significant-and-cl.html
- Thu Nov 12, 4:07 PM ET, SEC filing: Current report (Form 8-K) (SEC EDGAR) https://www.sec.gov/Archives/edgar/data/1390478/000139047826000021/sls-20261112.htm
- Thu Nov 12, 4:00 PM ET, SEC filing: Quarterly report (Form 10-Q) (SEC EDGAR) https://www.sec.gov/Archives/edgar/data/1390478/000139047826000020/sls-20260930.htm
- Tue Nov 10, 9:15 AM ET, SEC filing: Ownership stake over 5% (Schedule 13G) (SEC EDGAR) https://www.sec.gov/Archives/edgar/data/93751/000009375126000723/xslSCHEDULE_13G_X02/primary_doc.xml

## Questions

### Why did SLS stock go up on November 17?

SELLAS Life Sciences (SLS) released positive pivotal Phase 3 REGAL trial data at 7:00 AM ET on Tuesday, November 17, and the stock went from Monday’s $7.47 close to as high as $34.00 before the open. It finished the session +156.4% at $19.15 on 15.7 times its 20-day average volume. After the close it proposed a $150 million offering, and on Wednesday night priced it at $13.00 a share. The reaction describes the sequence and infers no cause.

### What did SELLAS Life Sciences announce on November 17, 2026?

SELLAS Life Sciences (SLS) released positive pivotal Phase 3 REGAL trial data at 7:00 AM ET on Tuesday, November 17. The company’s release and its Form 8-K are linked in the sources on this page.

### How did SLS stock trade on November 17?

SLS opened at $24.11, +222.8% from the prior close of $7.47, traded between $16.70 and $24.89 in the regular session and closed at $19.15, +156.4%, on 120M shares.

### What were the terms of the SLS offering?

SELLAS Life Sciences priced 11,538,462 shares of common stock at $13.00 a share, for gross proceeds of about $150 million, with a 30-day underwriters’ option on up to 1,730,769 more shares. The pricing was announced at 9:59 PM ET on Wednesday, November 18, and the offering was expected to close on November 20.

### What does LiveChart’s stack read on SLS now?

The read on this page is fixed at each moment it describes. LiveChart reads SLS on every bar as it trades: open it on LiveChart for the current stack bias, levels and every layer.

Chart: https://indicatorstack.com/chart/SLS. SLS catalyst history: https://indicatorstack.com/catalysts/stock/SLS

Each reaction describes what happened and when, infers no cause and takes no view on what comes next. Past reactions don’t predict future ones.

---

IndicatorStack: on-chart analysis for active traders. LiveChart (https://indicatorstack.com/chart) reads every bar of any US-listed ticker into one held stack bias, the levels to watch and Compass, free. Site guide: https://indicatorstack.com/llms.txt. Today's digest: https://indicatorstack.com/llms-full.txt. Risk Disclosure: https://indicatorstack.com/risk
